Zobrazeno 1 - 10
of 80
pro vyhledávání: '"Sujata P, Sarda"'
Autor:
Joan Mendivil, Maral DerSarkissian, Aleena Banerji, Lavanya Diwakar, Constance H. Katelaris, Paul K. Keith, Harold Kim, Gina Lacuesta, Markus Magerl, Charlotte Slade, William B. Smith, Zia Choudhry, Angela Simon, Sujata P. Sarda, Paula J. Busse
Publikováno v:
Allergy, Asthma & Clinical Immunology, Vol 19, Iss 1, Pp 1-13 (2023)
Abstract Background Hereditary angioedema (HAE) is a rare disease characterized by unpredictable, recurring subcutaneous or submucosal swelling. Without effective therapy, HAE can negatively impact patients’ quality of life. Management of HAE inclu
Externí odkaz:
https://doaj.org/article/78d076dcf6d34c9999fa3966bc528fe7
Autor:
Sujata P. Sarda, Magdalena Vanya, Ethan J. Schwartz, Keira Sorrells, Fumihiko Namba, Shinya Hirano, Alison McNulty, Linda Han, Alexandra Mangili
Publikováno v:
Biomedicine Hub, Vol 8, Iss 1, Pp 15-24 (2023)
Introduction: Extremely premature (EP) infants (
Externí odkaz:
https://doaj.org/article/ebaee3cd1ff3411fa4b04a2db191703c
Autor:
Meredith E. Mowitz, Wei Gao, Heather Sipsma, Pete Zuckerman, Hallee Wong, Rajeev Ayyagari, Sujata P. Sarda
Publikováno v:
Journal of Health Economics and Outcomes Research, Vol 9, Iss 2 (2022)
**Background:** The effect of gestational age (GA) on comorbidity prevalence, healthcare resource utilization (HCRU), and all-cause costs is significant for extremely premature (EP) infants in the United States. **Objectives:** To characterize real-
Externí odkaz:
https://doaj.org/article/5b6087529101443d94c8a9b86c3c2cbd
Publikováno v:
Journal of International Medical Research, Vol 49 (2021)
Objective Neurodevelopmental impairment (NDI) is a major complication of extreme prematurity. This systematic review was conducted to summarize the worldwide long-term prevalence of NDI associated with extreme prematurity. Methods Embase and MEDLINE
Externí odkaz:
https://doaj.org/article/95b23c7266404401947d469599ff71c2
Autor:
Sujata P. Sarda, Marie De La Cruz, Emuella M. Flood, Magdalena Vanya, David G. Hwang, Christopher N. Ta, Abhijit Narvekar
Publikováno v:
Health and Quality of Life Outcomes, Vol 17, Iss 1, Pp 1-10 (2019)
Abstract Background Acute infectious conjunctivitis is a common condition most frequently caused by viruses or bacteria. Clinical outcome assessments have been used to assess signs and symptoms of bacterial and viral conjunctivitis, but have not been
Externí odkaz:
https://doaj.org/article/598a2f8c5a5740d39183df52c213b690
Publikováno v:
Journal of Managed Care & Specialty Pharmacy. 29:S2-S11
Autor:
Meredith E. Mowitz, Wei Gao, Heather Sipsma, Pete Zuckerman, Hallee Wong, Rajeev Ayyagari, Sujata P. Sarda, Csaba Siffel
Publikováno v:
Pediatrics & Neonatology. 63:503-511
Infants born extremely premature (EP) (28 weeks gestational age) are at high risk of complications, particularly bronchopulmonary dysplasia (BPD), which can develop into chronic lung disease (CLD).The burden of respiratory complications in EP infants
Autor:
David Cella, Sujata P. Sarda, Ray Hsieh, Jesse Fishman, Zalmai Hakimi, Kate Hoffman, Mohammed Al-Adhami, Jameel Nazir, Katelyn Cutts, William R. Lenderking
Publikováno v:
Annals of Hematology. 101:1905-1914
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, chronic, acquired, hematologic, life-threatening disease characterized by thrombosis, impaired bone marrow function, and complement-mediated hemolysis. The PEGASUS phase III clinical trial demonstr
Publikováno v:
Frontiers in Pediatrics, Vol 7 (2019)
Background: Infants born extremely preterm are at high risk of developing bronchopulmonary dysplasia (BPD). This study aimed to assess the incremental health care burden of BPD and associated comorbidities among extremely preterm infants in the Unite
Externí odkaz:
https://doaj.org/article/7427ee10dd2d4d45961c90ca8cba6846
Autor:
David Dingli, Joana E. Matos, Kerri Lehrhaupt, Sangeeta Krishnan, Michael Yeh, Jesse Fishman, Sujata P. Sarda, Scott B. Baver
Publikováno v:
Annals of Hematology
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare and life-threatening disease with symptoms of hemolysis and thrombosis. Current therapies for this complement-mediated disease rely predominantly on inhibition of the C5 complement protein. However,